Skip to content

Safety and Efficacy Study of cipepofol and fosropofol Sodium for General Anesthesia Induction

Safety and Efficacy Study of cipepofol and fosropofol Sodium for General Anesthesia Induction

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126727
Enrollment
Unknown
Registered
2026-06-15
Start date
2026-06-15
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Success rate of anesthesia induction

Interventions

fospropofol group:NA
cipepofol group:NA

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18-65 years old, gender is not limited. 2.ASA grades I-III. 3.BMI 18-30 kg/m². 4.We plan to perform elective surgery under general anesthesia, with an estimated operation time of 1-3 hours. 5.Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of allergy to propofol, fospropofol disodium, and cipepofol. 2.Severe heart, liver, and kidney dysfunction (ALT/AST>2 times the upper limit of normal). 3.Difficult airway assessment as suspected difficult airway (Mallampati III-IV grade). 4.History of mental and neurological disorders, long-term use of sedatives and analgesics. 5.Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Success rate of general anesthesia induction;

Secondary

MeasureTime frame
Vital signs during anesthesia induction period;Incidence of injection pain;Incidence of adverse reactions during anesthesia induction;

Countries

China

Contacts

Public ContactYu Qi

Xuzhou Central Hospital

597562326@qq.com+86 516 83956183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 29, 2026